Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Leukemia

Clinical Trial at: Arizona Oncology - Tucson

A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

  • Details

ClinicalTrials.gov ID: NCT03406156
Diagnosis Type: CLL
USOR Number: 17106

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Arizona Oncology - Tucson

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  • Details

ClinicalTrials.gov ID: NCT03522246
Diagnosis Type: NA
USOR Number: 17182

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

GI Stromal Tumor (GIST)

Clinical Trial at: Arizona Oncology - Scottsdale

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

  • Details

ClinicalTrials.gov ID: NCT03465722
Diagnosis Type: NA
USOR Number: 18016

  • Practice Details

10460 N 92nd St, Suite 402
Scottsdale, Arizona 85258
P: (480) 860-2540

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Arizona Oncology - Tucson

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Melanoma

Clinical Trial at: Arizona Oncology - Tucson

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

  • Details

ClinicalTrials.gov ID: NCT02817633
Diagnosis Type: NA
USOR Number: 17063

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Lung Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

  • Details

ClinicalTrials.gov ID: NCT03318939
Diagnosis Type: NSCLC
USOR Number: 17143

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Phoenix

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, Arizona 85027
P: (602) 357-2400

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Glendale

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

7200 W Bell Road, Building A
Glendale, Arizona 85308
P: (623) 487-4822

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Tucson

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Tucson

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Scottsdale

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

10460 N 92nd St, Suite 402
Scottsdale, Arizona 85258
P: (480) 860-2540

More Details View Practice Page

Myelomas

Clinical Trial at: Arizona Oncology - Tucson

C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

  • Details

ClinicalTrials.gov ID: NCT03173092
Diagnosis Type: NA
USOR Number: 17081

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Myelomas

Clinical Trial at: Arizona Oncology - Tucson

C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

  • Details

ClinicalTrials.gov ID: NCT03173092
Diagnosis Type: NA
USOR Number: 17081

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Tucson

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Tucson

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Tucson

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Myelomas

Clinical Trial at: Arizona Oncology - Tucson

C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

  • Details

ClinicalTrials.gov ID: NCT03173092
Diagnosis Type: NA
USOR Number: 17081

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Tucson

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Phoenix

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Pages